Study wrapper · #966
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.
Rejili M, Hussain MS, Khan Y, et al. Vascular pharmacology. 2026.
DOI: 10.1016/j.vph.2025.107563PubMed: 41344603
Editor's note
A review of preclinical and clinical data on amylin receptor agonists for obesity, with cagrilintide as a lead agent and semaglutide referenced as a synergistic partner. Positions the drug class as promising but notes disease-modifying effects remain to be determined. Background-level material.
Plain-language abstract
This review covers amylin receptor biology and peptide-based amylin receptor agonists such as cagrilintide that are being studied for obesity, often alongside semaglutide.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Physiology & behaviorn=——2026
Supported
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacologyn=——2026